Podcast #62 Zomedica Pharmaceuticals Corp.

In many respects, animal health is an under-served field. Many of the medications used to treat animal health disorders are actually human drugs, developed for human physiology, and compounded drugs that have not been proven safe or effective for animal use. Similarly, diagnostic procedures for use on animals are also under-developed.

This is the underserved market that is currently being targeted by Zomedica Pharmaceuticals Corp. The Company originally started with a focus on veterinary pharmaceuticals and has since expanded its focus.

As Zomedica began advancing its pipeline of pet pharmaceutical products, the Company’s attention was drawn to a parallel gap in animal healthcare: diagnostics. ZOM has chosen to begin its efforts in this area with the development of a pet-specific diagnostic option for the most serious of diseases: cancer.

2017 was a milestone year for Zomedica. With a market cap of $223.3 million, the Company raised approximately $6.6 million in non-brokered capital alongside a $5 million unsecured working capital loan facility and listed on the NYSE American exchange.

On January 5, 2017; Zomedica announced a research agreement with Celsee Diagnostics, Inc. Celsee is a biotech innovator of rare cell capture, characterization and retrieval products in the emerging field of liquid biopsy. On December 21, 2017; the two companies took their relationship to the next level.

A licensing and supply agreement is now in place for Zomedica to develop and market Celsee’s liquid biopsy technology for veterinary application as a cancer diagnostic. Stockhouse recently caught up with ZOM’s Chief Operations Officer and Vice President of Product Development, Stephanie Morley, DVM, and Chief Financial Officer Shameze Rampertab, CPA, CA, to learn about the clinical and economic potential of this technology.